EVAX
Evaxion Biotech AS
NASDAQ: EVAX · HEALTHCARE · BIOTECHNOLOGY
$4.41
+3.52% today
Updated 2026-04-30
Market cap
$33.61M
P/E ratio
—
P/S ratio
4.47x
EPS (TTM)
$-1.00
Dividend yield
—
52W range
$1 – $12
Volume
0.0M
WallStSmart proprietary scores
21
out of 100
Grade: F
Strong Sell
Investment rating
3.7
Growth
D4.5
Quality
C2.0
Profitability
F5.3
Valuation
C+5/9
Piotroski F-Score
Moderate
-14.7
Altman Z-Score
Distress
—
Industry rank
—
View all highly rated stocks (75+) →206 stocks currently score above 75
Price targets
Analyst target
$11.25
+155.10%
12-Month target
—
—
Intrinsic (DCF)
$3.87
Margin of safety
+14.47%
1 Strong Buy3 Buy0 Hold0 Sell0 Strong Sell
Price chart
X-Ray snapshot
Strengths
+ 14.47% below intrinsic value
Risks
- Altman Z -14.71 — distress zone
- Thin margins at -102.40%
- Negative free cash flow $-6.66M
- Revenue declining -100.00% QoQ
Key financials
Revenue Net Income Free Cash Flow
| Metric | 2022 | 2023 | 2024 | 2025 | TTM |
|---|---|---|---|---|---|
| Revenue | $0.00 | $73000.00 | $3.34M | $7.55M | $7.53M |
| Net income | $-23.17M | $-22.13M | $-10.57M | $-7.73M | $-5.94M |
| EPS | — | — | — | — | $-1.00 |
| Free cash flow | $-26.07M | $-17.78M | $-12.94M | $-6.66M | $-6.66M |
| Profit margin | — | -30,308.22% | -316.00% | -102.38% | -102.40% |
Peer comparison
Smart narrative
Evaxion Biotech AS trades at $4.41. Our Smart Value Score of 21/100 indicates the stock is weak. The company scores 5/9 on the Piotroski F-Score. With an Altman Z-Score of -14.71, it sits in the distress. TTM revenue stands at $7.53M. with profit margins at -102.40%. Our DCF model estimates intrinsic value at $3.87.
Frequently asked questions
What is Evaxion Biotech AS's stock price?
Evaxion Biotech AS (EVAX) trades at $4.41.
Is Evaxion Biotech AS overvalued?
Smart Value Score 21/100 (Grade F, Strong Sell). DCF value $3.87.
What is the price target of Evaxion Biotech AS (EVAX)?
The analyst target price is $11.25, representing +155.1% upside from the current price of $4.41.
What is the intrinsic value of Evaxion Biotech AS (EVAX)?
Based on our DCF model, intrinsic value is $3.87, a +14.5% margin of safety versus $4.41.
What is Evaxion Biotech AS's revenue?
TTM revenue is $7.53M.
Piotroski F-Score?
5/9 — moderate financial health.
Altman Z-Score?
-14.71 — distress.
Company info
SectorHEALTHCARE
IndustryBIOTECHNOLOGY
CountryUSA
ExchangeNASDAQ
CurrencyUSD
Quick metrics
P/S ratio4.47x
ROE-100.20%
Beta0.20
50D MA$3.73
200D MA$4.24
Shares out0.01B
Float0.28B
Short ratio—
Avg volume0.0M
Performance
1 week—
1 month—
3 months—
YTD—
1 year—
3 years—
5 years—